secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuwellis, Inc. (NUWE)
CIK:        0001506492
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001140361-23-023593
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuwellis Q1 revenue down 5% to $1.8M; net loss widens to $6.5M
--------------------------------------------------------------

- Revenue $1.8M, 5% decline from $1.9M in Q1 2022; gross margin improved 120 bps to 58.4%.
- Heart Failure segment revenue up 21% YoY; Pediatrics down 28%, Critical Care down 4%.
- Net loss $6.5M ($5.76 loss per share) vs $4.5M ($42.45 loss per share) in prior year; includes $755K non-cash warrant revaluation expense.
- Cash, equivalents and marketable securities $12.1M at March 31, 2023; no debt.
- CEO cites new clinical evidence driving heart failure growth; focused on making Aquadex ultrafiltration therapy standard of care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506492/000114036123023593/0001140361-23-023593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506492/000114036123023593/brhc20052638_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-023593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer